FDA approves Dupixent for atopic dermatitis in adolescents | Cafepharma
Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
advertise
Legal Help
login/register
You are here
Home » FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
FDA approves Dupixent for atopic dermatitis in adolescents
Submitted by admin on March 11, 2019 - 10:15pm
Source:
BioCentury
News Tags:
Dupixent
Regeneron
Sanofi
FDA
atopic dermatitis
Headline:
FDA approves Dupixent for atopic dermatitis in adolescents
snippet:
FDA on Monday approved the first biologic for adolescents with moderate-to-severe atopic dermatitis, Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter | social media-pharma | social media-med device | cafebanking
Copyright © 2019,